Lineage Cell Therapeutics, Inc.
LCTX
$1.22
-$0.01-0.41%
AMEX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.73M | 6.61M | 3.68M | 2.77M | 1.50M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.73M | 6.61M | 3.68M | 2.77M | 1.50M |
| Cost of Revenue | 4.23M | 8.30M | 3.28M | 3.15M | 3.15M |
| Gross Profit | -784.00K | -1.70M | 405.00K | -380.00K | -1.65M |
| SG&A Expenses | 5.08M | 4.85M | 4.19M | 4.56M | 4.86M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.32M | 13.16M | 7.47M | 7.71M | 8.01M |
| Operating Income | -7.59M | -6.55M | -3.79M | -4.94M | -6.51M |
| Income Before Tax | -4.79M | -4.39M | -29.75M | -30.36M | -4.14M |
| Income Tax Expenses | -- | -5.28M | -- | -- | -- |
| Earnings from Continuing Operations | -4.79M | 892.00K | -29.75M | -30.36M | -4.14M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -23.00K | -41.00K | -29.00K | -100.00K | 4.00K |
| Net Income | -4.81M | 851.00K | -29.78M | -30.46M | -4.14M |
| EBIT | -7.59M | -6.55M | -3.79M | -4.94M | -6.51M |
| EBITDA | -7.41M | -6.36M | -3.61M | -4.77M | -6.34M |
| EPS Basic | -0.02 | 0.00 | -0.13 | -0.13 | -0.02 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.08 | -0.04 | -0.01 |
| EPS Diluted | -0.03 | 0.00 | -0.13 | -0.13 | -0.02 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.08 | -0.04 | -0.01 |
| Average Basic Shares Outstanding | 245.03M | 237.17M | 228.85M | 228.36M | 226.05M |
| Average Diluted Shares Outstanding | 261.18M | 237.17M | 228.85M | 228.36M | 226.05M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |